Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 342 participants.
Also called NCT01032395
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 342 participants
- Sponsor
- Chiltern Pesquisa Clinica Ltda
- Registry
-
NCT01032395
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Brazil
- Registry status
- Completed
Technical summary
Registry record NCT01032395. Randomized; no masking; primary purpose prevention. Start 2010-03 (registry gives no type); primary completion 2011-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus
- Condition
- H1N1 Influenza Virus
- Condition
- Chronic Pulmonary Disease
- Condition
- Chronic Heart Disease
- Condition
- Diabetes Mellitus
- Intervention (Biological)
- Focetria®
- Intervention (Biological)
- Fluad®
- Intervention (Biological)
- Begrivac®
- Lead sponsor
- Chiltern Pesquisa Clinica Ltda
Record details
- Record id
cardio:ct-nct01032395- Content hash
6945e700ce658f296fd4863d46628d0b1875fd0a38f2412e19c4d7a73ca5e009